AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15689088 — intervention group
Group type: COMPARATOR
Intervention: DTPa-IPV-Hib vaccine at 1 1/2, 3 and 5 months of age with separate HBV vaccine at 1 and 5 months of age
Number of subjects: 150
Study 15689088 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa HBV-IPV-Hib vaccine
Number of subjects: 150
Study 11694208 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR, 150 mg/day
Number of subjects: 19
Study 11694208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9450160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivagabine (450-900 mg/d by oral route)
Number of subjects: 90
Study 9450160 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical quantities to pivagabine)
Number of subjects: 90
Study 8565166 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ICD implantation
Number of subjects: 60
Study 8565166 — intervention group
Group type: COMPARATOR
Intervention: EP-guided strategy
Number of subjects: 60
Study 8565166 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs as sole therapy
Number of subjects: 60
Study 2338696 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt diet
Number of subjects: 0
Study 2338696 — intervention group
Group type: COMPARATOR
Intervention: Low salt diet
Number of subjects: 0
Study 7397057 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.2 mg
Number of subjects: 12
Study 7397057 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.4 mg
Number of subjects: 12
Study 7397057 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.6 mg
Number of subjects: 12
Study 7397057 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.2 mg (night)
Number of subjects: 12
Study 7397057 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.4 mg (night)
Number of subjects: 12
Study 7397057 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.6 mg (night)
Number of subjects: 12
Study 31694094 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 μg
Number of subjects: 548
Study 31694094 — intervention group
Group type: COMPARATOR
Intervention: tiotropium 5 μg
Number of subjects: 548
Study 31694094 — intervention group
Group type: COMPARATOR
Intervention: olodaterol 5 μg
Number of subjects: 548
Study 29021000 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation fluid at body temperature (37 oC)
Number of subjects: 600
Study 29021000 — intervention group
Group type: COMPARATOR
Intervention: Irrigation fluid at room temperature
Number of subjects: 600
Study 25390281 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate nasal prongs (Salter)
Number of subjects: 45
Study 25390281 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcated nasal prongs (Hudson)
Number of subjects: 45
Study 25390281 — intervention group
Group type: COMPARATOR
Intervention: Multi-vented nasal cannula (Oridion)
Number of subjects: 45
Study 25390281 — intervention group
Group type: COMPARATOR
Intervention: Dual-vented nasal cannula (Medline)
Number of subjects: 45
Study 25089344 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective communication
Number of subjects: 50
Study 25089344 — intervention group
Group type: COMPARATOR
Intervention: Standard communication
Number of subjects: 50
Study 21703750 — intervention group
Group type: EXPERIMENTAL
Intervention: Post exercise changes of urinary leukotriene E4 (LTE4) concentration in children with EIA
Number of subjects: 25
Study 21703750 — intervention group
Group type: COMPARATOR
Intervention: Post exercise changes of urinary leukotriene E4 (LTE4) concentration in healthy controls
Number of subjects: 25
Study 21703750 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes of LTE4 concentration post ECT in children with EIA
Number of subjects: 25
Study 21703750 — intervention group
Group type: COMPARATOR
Intervention: Changes of LTE4 concentration post ECT in healthy controls
Number of subjects: 25
Study 20214067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranquilizing and allaying excitement needling method (acupuncture at Sishencong, Shenmen, and Sanyinjiao)
Number of subjects: 60
Study 20214067 — intervention group
Group type: COMPARATOR
Intervention: Eight confluence points selected needling method (acupuncture at Shenmai and Zhaohai)
Number of subjects: 60
Study 16949180 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine supplements (30 g/day) for 15 days, initiated at least 3 days before chemotherapy
Number of subjects: 51
Study 16949180 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 51
Study 16949180 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine supplements (OGS)
Number of subjects: 51
Study 16949180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy group
Number of subjects: 51
Study 16338265 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin 15 ng/(kg.min)
Number of subjects: 24
Study 16338265 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin 30 ng/(kg.min)
Number of subjects: 24
Study 16338265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11939925 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. diclofenac 75 mg followed by oral diclofenac 150 mg/day for 3 days
Number of subjects: 64
Study 11939925 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoprofen 100 mg followed by oral ketoprofen 300 mg/day for 3 days
Number of subjects: 64
Study 11939925 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 64
Study 9403746 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral vein catheterization
Number of subjects: 61
Study 9403746 — intervention group
Group type: COMPARATOR
Intervention: Superior vena cava catheterization
Number of subjects: 61
Study 8495452 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0
Study 8495452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3305795 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) combined with Adriamycin (FA)
Number of subjects: 189
Study 3305795 — intervention group
Group type: EXPERIMENTAL
Intervention: FA plus methyl‐CCNU (MeFA)
Number of subjects: 189
Study 3305795 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 189
Study 28345160 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g l-carnitine + carbohydrate (CARN)
Number of subjects: 21
Study 28345160 — intervention group
Group type: COMPARATOR
Intervention: 80 g carbohydrate (CON)
Number of subjects: 21
Study 28345160 — intervention group
Group type: COMPARATOR
Intervention: CARN and CON
Number of subjects: 21
Study 27256768 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bowel preparation with enema
Number of subjects: 45
Study 27256768 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bowel preparation with suppository
Number of subjects: 45
Study 27256768 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 45
Study 25577862 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (Wolfgang Amadeus Mozart 'Sonata K. 448')
Number of subjects: 35
Study 25577862 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 35
Study 25577862 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure
Number of subjects: 35
Study 22626878 — intervention group
Group type: COMPARATOR
Intervention: Routine fluid administration (Group A)
Number of subjects: 40
Study 22626878 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid administration (Group B)
Number of subjects: 40
Study 20889234 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hypericin with visible light irradiation (8 to 20 J/cm²), applied twice weekly for 6 weeks
Number of subjects: 0
Study 20889234 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 0
Study 18540715 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback birthday card intervention
Number of subjects: 281
Study 18540715 — intervention group
Group type: COMPARATOR
Intervention: No birthday card (Control)
Number of subjects: 281
Study 15840623 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 103
Study 15840623 — intervention group
Group type: COMPARATOR
Intervention: Prehospital fibrinolysis (rt-PA)
Number of subjects: 103
Study 15840623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue angioplasty
Number of subjects: 103
Study 12494299 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt (450 g for 4 months)
Number of subjects: 20
Study 12494299 — intervention group
Group type: COMPARATOR
Intervention: Partially skimmed milk (450 g for 4 months)
Number of subjects: 20
Study 12494299 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 20
Study 10075361 — intervention group
Group type: EXPERIMENTAL
Intervention: No drains (test group)
Number of subjects: 119
Study 10075361 — intervention group
Group type: COMPARATOR
Intervention: Drains (control group)
Number of subjects: 119
Study 7731155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast agent (meglumine/sodium diatrizoate)
Number of subjects: 1196
Study 7731155 — intervention group
Group type: COMPARATOR
Intervention: Nonionic contrast agent (iohexol)
Number of subjects: 1196
Study 7731155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast agent (meglumine/sodium diatrizoate) with RI
Number of subjects: 1196
Study 7731155 — intervention group
Group type: COMPARATOR
Intervention: Nonionic contrast agent (iohexol) with RI
Number of subjects: 1196
Study 7731155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast agents
Number of subjects: 1196
Study 1873746 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-neon laser (632.8 nm at 10 mW) applied for three minutes immediately following surgery
Number of subjects: 15
Study 1873746 — intervention group
Group type: COMPARATOR
Intervention: Control side (similar technique without activation of the laser beam)
Number of subjects: 15
Study 6626426 — intervention group
Group type: COMPARATOR
Intervention: 10 mg pinacidil (single oral dose)
Number of subjects: 6
Study 6626426 — intervention group
Group type: COMPARATOR
Intervention: 20 mg pinacidil (mean dose, twice daily for 3‐7 weeks)
Number of subjects: 6
Study 6626426 — intervention group
Group type: COMPARATOR
Intervention: Pinacidil (chronic treatment)
Number of subjects: 6
Study 30179656 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin–tazobactam 4 g/0.5 g at the time of intubation and 12 h later
Number of subjects: 84
Study 30179656 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 30179656 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin–tazobactam
Number of subjects: 84
Study 29769663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 57
Study 29769663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 26181769 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (measuring thyroid function and thyroid antibody in early pregnancy)
Number of subjects: 1671
Study 26181769 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement therapy (for 105 SCH and 4 hypothyroid women in screening group)
Number of subjects: 1671
Study 26181769 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular follow‐up visits (for women in screening group who did not take medicine)
Number of subjects: 1671
Study 26181769 — intervention group
Group type: COMPARATOR
Intervention: Control group (serum stored and measured shortly after delivery)
Number of subjects: 1671
Study 25151903 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise from 34 weeks of gestational age to delivery
Number of subjects: 239
Study 25151903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured walking exercise)
Number of subjects: 239
Study 25151903 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 239
Study 25151903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239
Study 21947137 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg delayed-release (DR) weekly (either before or after breakfast)
Number of subjects: 922
Study 21947137 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg immediate-release (IR) daily
Number of subjects: 922
Study 19942104 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood therapy (ABT) - gluteal intramuscular reinjection of venous blood three times a week
Number of subjects: 139
Study 19942104 — intervention group
Group type: COMPARATOR
Intervention: Placebo - sterile sodium chloride solution
Number of subjects: 139
Study 17453747 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril plus hydrochlorothiazide
Number of subjects: 11454
Study 17453747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus benazepril
Number of subjects: 11454
Study 15951245 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMA kwa Vijana intervention (teacher-led, peer-assisted sexual health education, training of health workers, peer condom promotion, community activities)
Number of subjects: 9645
Study 15951245 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9645
Study 12174785 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg quinine twice a day for 3 days (group 1)
Number of subjects: 0
Study 12174785 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg quinine twice a day for 3 days followed by a total dose of 25 mg chloroquine base over 3 days (group 2)
Number of subjects: 0
Study 12174785 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg chloroquine base given in 2 daily doses for 3 days (group 3)
Number of subjects: 0
Study 12174785 — intervention group
Group type: COMPARATOR
Intervention: sulfadoxine-pyrimethamine (group 4)
Number of subjects: 0
Study 9844152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered peritoneal dialysis solution (34 mmol/liter)
Number of subjects: 123
Study 9844152 — intervention group
Group type: COMPARATOR
Intervention: Lactate-buffered peritoneal dialysis solution (35 mmol/liter)
Number of subjects: 123
Study 7813599 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxindole 1 mg
Number of subjects: 6
Study 7813599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2673441 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbimide (CC)
Number of subjects: 128
Study 2673441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 851140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 10 per cent ethanol
Number of subjects: 135
Study 851140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ritodrine for 12 hours followed by oral ritodrine
Number of subjects: 135
Study 31419791 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy in 3 fractions
Number of subjects: 60
Study 31419791 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 Gy in 3 fractions
Number of subjects: 60
Study 31419791 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy in 3 fractions
Number of subjects: 60
Study 31419791 — intervention group
Group type: COMPARATOR
Intervention: 24 Gy in 3 fractions
Number of subjects: 60
Study 31419791 — intervention group
Group type: COMPARATOR
Intervention: 30 Gy in 3 fractions
Number of subjects: 60
Study 29122789 — intervention group
Group type: EXPERIMENTAL
Intervention: DEMO score obtained
Number of subjects: 383
Study 25215434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dialysis
Number of subjects: 140
Study 25215434 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose dialysis
Number of subjects: 140
Study 25215434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialyzer
Number of subjects: 140
Study 25215434 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialyzer
Number of subjects: 140
Study 23750466 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 240
Study 23750466 — intervention group
Group type: COMPARATOR
Intervention: Literature Control (LC)
Number of subjects: 240
Study 20855549 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C ≥6.5%
Number of subjects: 12485
Study 20855549 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C 5.7-<6.5%
Number of subjects: 12485
Study 18645246 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (DRW)
Number of subjects: 27
Study 18645246 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 27
Study 16946657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and methylprednisolone (30 mL 0.25% bupivacaine and 40 mg methylprednisolone) before wound closure
Number of subjects: 75
Study 16946657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine alone (30 mL 0.25% bupivacaine) before closure
Number of subjects: 75
Study 16946657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and methylprednisolone (30 mL 0.25% bupivacaine and 40 mg methylprednisolone) before incision
Number of subjects: 75
Study 16946657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine alone (30 mL 0.25% bupivacaine) before incision
Number of subjects: 75
Study 16946657 — intervention group
Group type: COMPARATOR
Intervention: Control (30 mL 0.9% NaCl before wound closure)
Number of subjects: 75
Study 12880362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450-nm laser treatment with dynamic cooling
Number of subjects: 0
Study 12880362 — intervention group
Group type: COMPARATOR
Intervention: Control side (no treatment)
Number of subjects: 0
Study 10875487 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 200 mg twice daily for 8 weeks
Number of subjects: 17
Study 10875487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9180600 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg in one oral dose
Number of subjects: 130
Study 9180600 — intervention group
Group type: EXPERIMENTAL
Intervention: two oral doses of 30 mg/kg at a 6-hr interval
Number of subjects: 130
Study 8257124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramicrosize griseofulvin (UMSG) at 660 mg/day
Number of subjects: 109
Study 8257124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramicrosize griseofulvin (UMSG) at 990 mg/day
Number of subjects: 109
Study 8257124 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole at 100 mg/day
Number of subjects: 109
Study 8257124 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects (nausea, diarrhea, headache)
Number of subjects: 109
Study 2984100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg sublingually
Number of subjects: 7
Study 2984100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31232495 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA-related ICH
Number of subjects: 5900
Study 31232495 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA-ri
Number of subjects: 5900
Study 29794285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate treatment
Number of subjects: 12
Study 29794285 — intervention group
Group type: COMPARATOR
Intervention: Control (usual treatment)
Number of subjects: 12
Study 26627899 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortifying milk on measured composition according to birth weight criteria and postmenstrual age (PMA)
Number of subjects: 0
Study 26627899 — intervention group
Group type: COMPARATOR
Intervention: Routine practice of fortifying on assumed milk composition
Number of subjects: 0
Study 23755093 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation at 2 or 3 L/min for 72 hours
Number of subjects: 289
Study 23755093 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (room air)
Number of subjects: 289
Study 22198653 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nail (n = 56)
Number of subjects: 104
Study 22198653 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard large fragment medial plate (n = 48)
Number of subjects: 104
Study 22198653 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (n = 104)
Number of subjects: 104
Study 22198653 — intervention group
Group type: COMPARATOR
Intervention: Unemployed patients (n = 104)
Number of subjects: 104
Study 20372111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Crohn's Disease Activity Index (PCDAI)
Number of subjects: 437
Study 20372111 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDAI for mild disease
Number of subjects: 437
Study 20372111 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDAI for moderate disease
Number of subjects: 437
Study 20372111 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDAI for severe disease
Number of subjects: 437
Study 20372111 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDAI response measurement
Number of subjects: 437
Study 20372111 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability of PCDAI
Number of subjects: 437
Study 20372111 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsiveness of PCDAI
Number of subjects: 437
Study 18528903 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 10
Study 15882228 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml erythrosine mouthwash for 15 s rinsing period
Number of subjects: 30
Study 15882228 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml erythrosine mouthwash for 30 s rinsing period
Number of subjects: 30
Study 15882228 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml erythrosine mouthwash for 60 s rinsing period
Number of subjects: 30
Study 15882228 — intervention group
Group type: COMPARATOR
Intervention: 10 ml erythrosine mouthwash for 90 s rinsing period
Number of subjects: 30
Study 12947730 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 58
Study 12947730 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 58
Study 10475181 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive treatment strategy
Number of subjects: 2457
Study 10475181 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive treatment strategy
Number of subjects: 2457